Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPH046
- Development stage
- Preclinical
- Lead developer
- Disruptive Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DPH046 is a preclinical-stage oral small molecule drug candidate being developed by Disruptive Pharma for the treatment of leukemia. The drug is a reformulation of an established active pharmaceutical ingredient (API) utilizing the company's proprietary Formulite technology platform. This platform employs mesoporous magnesium carbonate (MMC) as a high-surface-area carrier to stabilize the API in an amorphous state, which significantly enhances its solubility and oral bioavailability compared to standard formulations. By improving the pharmacokinetic profile of existing oncology agents, DPH046 aims to optimize therapeutic efficacy and potentially improve patient outcomes in leukemia.
Beyond the preview
Go deeper on DPH046.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPH046.